Key Takeaways ARTISTRY-1 showed Gilead's once-daily bictegravir/lenacapavir matched complex HIV regimens at week 48.The combo was generally well tolerated, with no significant or new safety concerns reported.Gilead plans to file ARTISTRY data with regulators as it advances its broader HIV treatment portfolio.Gilead Sciences, Inc. (GILD) announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...